{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"3.7","value":"2.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.","id":"OG000","title":"TKI258"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) included all patients who received at least one dose of study drug.\n\nFAS was used for the analysis of efficacy endpoints.","reportingStatus":"POSTED","timeFrame":"36 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}